Biohaven tumbles as migraine drug efficacy fails to impress investors
(Reuters) - Biohaven Pharmaceutical Holding Co Ltd said its migraine treatment met the main goals in two late-stage studies but the efficacy data failed to differentiate when compared with rival treatments in a crowded field.
from Reuters: Health News https://reut.rs/2GcIXEW
http://bit.ly/2zwRqiM